Late Diagnosis of Prader-Willi Syndrome in an Adolescent With Significant Complications of Type 2 Diabetes
Abstract
Youth-onset type 2 diabetes (YO-T2D) is on the rise and disproportionately affects those from low socioeconomic status and specific ethnic and racial minority groups. YO-T2D has a more aggressive phenotype than adult-onset T2D. We present a case of a 14-year-old patient who presented after a fall and was found to be acutely unwell with significant peripheral edema. Initial investigations indicated hyperglycemic hyperosmolar state, acute kidney injury, and nephrotic range proteinuria, leading to a new diagnosis of T2D. Subsequent evaluation revealed mild retinopathy and diabetic nephropathy. Sixteen months prior, glycated hemoglobin (HbA1c) was > 16% (reference range, ≤ 6.0%) with no treatment initiated at that time. The patient was initially treated with multiple daily insulin injections prior to starting empagliflozin-metformin. The presence of developmental delays, short stature, and hypogonadism prompted genetic testing, which confirmed a diagnosis of Prader-Willi syndrome, a neurodevelopmental disorder associated with hyperphagia and early-onset obesity. This case underscored the severity of YO-T2D, risks of delayed healthcare access, and considerations for optimal diabetes management.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.